Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned a consensus rating of “Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $13.42.

FOLD has been the subject of several recent analyst reports. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. BidaskClub raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Bank of America Corporation decreased their target price on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, May 25th. Cowen and Company reaffirmed a “buy” rating and set a $16.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $12.00 target price on shares of Amicus Therapeutics in a research note on Friday, June 30th.

Amicus Therapeutics (NASDAQ FOLD) traded up 0.55% during midday trading on Friday, reaching $12.91. The company’s stock had a trading volume of 8,043,231 shares. Amicus Therapeutics has a 1-year low of $4.41 and a 1-year high of $13.64. The company’s 50-day moving average price is $8.63 and its 200-day moving average price is $6.95. The company’s market capitalization is $1.85 billion.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. Amicus Therapeutics had a negative return on equity of 65.75% and a negative net margin of 1,319.07%. The business had revenue of $4.20 million during the quarter, compared to the consensus estimate of $4.16 million. Amicus Therapeutics’s revenue for the quarter was up 50.0% compared to the same quarter last year. On average, analysts predict that Amicus Therapeutics will post ($1.45) earnings per share for the current fiscal year.

In related news, insider Jay Barth sold 30,000 shares of the stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $10.00, for a total value of $300,000.00. Following the completion of the sale, the insider now directly owns 64,184 shares of the company’s stock, valued at approximately $641,840. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Hung Do sold 29,914 shares of the stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $8.00, for a total value of $239,312.00. Following the completion of the sale, the insider now directly owns 474,438 shares of the company’s stock, valued at $3,795,504. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.

A number of large investors have recently made changes to their positions in FOLD. Principal Financial Group Inc. increased its stake in shares of Amicus Therapeutics by 1.8% in the first quarter. Principal Financial Group Inc. now owns 26,883 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 487 shares in the last quarter. KCG Holdings Inc. increased its stake in Amicus Therapeutics by 1.1% in the first quarter. KCG Holdings Inc. now owns 66,066 shares of the biopharmaceutical company’s stock worth $471,000 after buying an additional 743 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Amicus Therapeutics by 5.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 102,462 shares of the biopharmaceutical company’s stock worth $731,000 after buying an additional 5,041 shares during the period. Creative Planning increased its stake in Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 5,900 shares during the period. Finally, Berson & Corrado Investment Advisors LLC increased its stake in Amicus Therapeutics by 16.8% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 47,525 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 6,825 shares during the period.

WARNING: “Brokerages Set Amicus Therapeutics, Inc. (FOLD) Target Price at $13.42” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/07/17/brokerages-set-amicus-therapeutics-inc-fold-target-price-at-13-42.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.